ArticleEuropean urology open science2024

The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.

F Johannes P van Valenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.